HVA/VMA Ratio

Your body turns dopamine into one waste acid and norepinephrine plus adrenaline into another, then clears both in urine. Comparing the two asks whether the enzyme that turns dopamine into norepinephrine is keeping up. When that step stalls, the dopamine side dominates.

That tipped balance carries real diagnostic weight in two places: an inherited copper transport disease that shows up in infancy, and neuroblastoma, a tumor of developing nerve tissue in children. Outside those settings it's a research number without established meaning. This is a marker that can add evidence in the right context, not one that rules disease out.

The Two Acids and the Step Between Them

HVA is homovanillic acid. It is what's left after your body finishes breaking down dopamine. VMA is vanillylmandelic acid. It is what's left after it finishes with norepinephrine and adrenaline.

Dopamine sits upstream of both, because an enzyme called dopamine beta-hydroxylase converts dopamine into norepinephrine. That enzyme needs copper to work. If copper can't reach it, or if tumor cells stay too immature to run that step well, dopamine backs up and exits through the HVA route instead.

Copper Transport and Menkes Disease

Menkes disease is an inherited disorder, carried on the X chromosome, in which copper can't move properly out of the gut and into tissues. The converting enzyme starves for copper and the ratio climbs. In a series of 15 affected infants, every one had a much higher ratio than controls, and fewer than 1 in 500 controls crossed the study's screening threshold.

That separation is why the ratio became a screening tool for the disease. Blood copper and ceruloplasmin, the protein that carries copper through the bloodstream, can be hard to read in the first weeks of life, which is exactly when the diagnosis matters. The ratio looks at the enzyme's output rather than at copper itself.

Neuroblastoma and the MYCN Question

Neuroblastoma cells with a dopamine-heavy pattern tend to be less mature. In 73 children with the tumor, the ratio ran about four times higher when the tumor carried extra copies of MYCN, a gene tied to aggressive disease. In that comparison the ratio told amplified from non-amplified tumors apart about nine times out of ten, though the chosen cutoff still missed some amplified tumors.

The reasoning behind that goes back decades. A high ratio means the tumor is making dopamine but not finishing the next step well. Older urinary studies found that children whose balance tipped that way often had worse survival, including some with advanced disease.

As a diagnostic test rather than a prognostic one, the two acids together caught about 86 of every 100 children who had neuroblastoma and correctly cleared about 92 of every 100 who didn't. A wider eight-metabolite urine panel finds more cases, but it also flags more controls. That is why this belongs in a clinical workup, not mass screening.

Sources, in row order: Peitzsch et al.; Matsuo et al.; Matser et al.

If a child in your family is being evaluated for neuroblastoma, this ratio is not what makes or breaks the diagnosis. Imaging and tissue pathology do that. What the ratio can add is an early, cheap hint about tumor biology from a urine sample while the rest is still pending.

Why a Normal Result Doesn't Clear You

Around 1.5 million infants were once screened with these two acids to catch neuroblastoma before it declared itself. Elevated levels found roughly 73% of cases later detected. About one in four later-detected cases had not shown elevated levels at screening, and the missed cases were often the aggressive ones.

Mass screening was abandoned because it didn't lower deaths from the disease. A normal ratio does not mean there's no tumor, and an unusual ratio does not mean there is one.

So stop thinking of this as a good-number, bad-number marker. It's a pattern readout, telling you which chemical route a set of cells is using. A high ratio in an infant with neurological signs points toward copper transport, and the same high ratio in a child with a known abdominal mass points toward a less mature tumor.

In a healthy adult, the same number points at nothing in particular, because nobody has shown what it predicts there.

The Wrong Test for Pheochromocytoma

Adults who go looking for this test often have a pheochromocytoma in mind, the adrenal tumor that floods the body with adrenaline and causes blood pressure spikes. VMA is a weak test for it. Across studies its sensitivity runs between 46% and 77%, so it misses anywhere from roughly a quarter to more than half of cases.

Plasma free metanephrines catch 97 to 99 out of 100. The reason is dilution. Your body produces these two acids everywhere, constantly, so a tumor's contribution gets lost in a large background. Metanephrines sit closer to the source. If the question is a pheochromocytoma, order metanephrines.

When the Ratio Runs Low

A low ratio has no validated meaning in a healthy adult. The closest human evidence comes from 109 patients with craniopharyngioma, a tumor near the base of the brain, where severe obesity went along with reduced levels of both acids. That study measured each acid separately rather than the ratio, and it points at blunted sympathetic nerve output from damage to the hypothalamus. That is not evidence for interpreting a low ratio in an otherwise well person.

Why a Single Reading Can Fool You

Urine breakdown products move around within the same person from day to day. Treat one reading as a data point, not a verdict.

• Medications: amitriptyline and imipramine, two older antidepressants, lowered urinary breakdown products of the adrenaline family in 95 people treated for depression. They don't cause any condition this marker detects. They just move the number.
• Painkillers and assay interference: ibuprofen breakdown products interfered with an older lab method for separating these two acids and produced misleading results. Newer assays are more selective, but flag recent ibuprofen anyway.
• Food: one child's olive-heavy meal produced a false suspicion of relapsed neuroblastoma. In a controlled human study using newer lab methods, though, diet explained very little of the variation between people.
• Timing and collection: VMA follows a daily rhythm that cold exposure shifted in a small experiment. Results are reported against creatinine, so anything that changes creatinine output, including muscle mass and kidney function, can move the normalized number without changing the pathway itself.

Tracking Your Trend

Serial testing is where these breakdown products make the most sense, mostly in cancer surveillance. In 153 people with high-risk neuroblastoma who reached complete remission, urine measurements tracked over time helped identify who was at higher risk of relapse and death. That study followed the individual metabolites and a wider panel, not this ratio alone.

Spot urine is usually enough for this clinical question. In 400 neuroblastoma patients and 571 controls, spot urine and full-day collection had similar diagnostic sensitivity, and one infant was followed through repeated spot samples across the first year of life without trouble. Collect at the same time of day each time so your own results compare more cleanly.

If you're tracking this as part of an organic acids panel and you feel well, there is no validated medical cadence. Repeat mainly to confirm an unexpected result after a cleaner collection, or as part of the same broader panel strategy. If you or a child are in active tumor surveillance, follow the oncology schedule and don't let this substitute for it.

What an Odd Result Should Make You Do

Repeat it first, with a clean collection. Same time of day, recent ibuprofen flagged, and no olive-heavy or otherwise unusual meal beforehand. A result that doesn't reproduce isn't worth acting on.

If it holds, look at the two components instead of the ratio. A high ratio driven by low VMA points at the conversion step, which makes serum copper and ceruloplasmin worth checking. A high ratio driven by high HVA points at dopamine production and is a different conversation.

If the real worry is a tumor that pumps out adrenaline-family chemicals, the next test is plasma free metanephrines and normetanephrines, not a second ratio. For a child, a pediatric oncologist runs that workup alongside imaging and tissue pathology. For a suspected inherited copper or enzyme problem, a metabolic geneticist is the right specialist.

The pattern that usually warrants restraint is a ratio that stays unusual, normal copper, normal metanephrines, no symptoms, and nothing on any imaging you had a reason to do anyway. In adults, that pattern is currently uninterpretable. Acting on it means chasing a number nobody has tied to an outcome.